Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Aptevo Therapeutics Inc.

APVO · Nasdaq · CIK 0001671584 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

13 Form 4 transaction lines observed in the same window
0 sales · 13 option, withholding, award, gift or other lines

Last qualifying purchase2025-11-10 · Grant Grady III · $20.1K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesNone
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
White Marvin LExecutive Chair
○○○
Huebner DirkSVP, CMO
○○
Taylor DaphneSVP, CFO
○
Niederhuber JohnDirector
○
Lamothe Jeffrey G.President and CEO
○
Kwon SoYoungSVP, GC, BD & Corp Affairs
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 4 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-11-10 · Grant Grady III.

Recent Form 4 activity

1Purchases
0Sales
13Other Form 4 lines
11SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER13 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-2.1%
3M
-53.3%
6M
-57.0%
12M
-92.8%

Volatility & liquidity

Volatility
144.9%
Beta
1.68
Avg daily value
USD 206,420

Valuation

Market cap
USD 3.3M
P/E
0.0×

Fundamentals

Profit margin
0.0%
ROE
-149.4%
Industry
Biotechnology

Market data

Price data up to: 2026-10-07 · Price source: OpenBB/yfinance · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · From Yahoo Finance: Market cap, P/E, Profit margin · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
119,457
Previous report
187,942
Avg daily volume
69,825
Days to cover
1.7

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-11-10Grant Grady IIIPurchase (P)Common Stock13,513USD 1.49USD 20,134SEC filing ↗
2020-11-06TANG CAPITAL MANAGEMENT LLC; TANG CAPITAL PARTNERS LP; TANG KEVIN CPurchase (P)Common Stock174,277USD 22.73USD 3,961,898SEC filing ↗
2020-11-05TANG CAPITAL MANAGEMENT LLC; TANG CAPITAL PARTNERS LP; TANG KEVIN CPurchase (P)Common Stock625,723USD 18.78USD 11,750,307SEC filing ↗
2020-11-04TANG CAPITAL MANAGEMENT LLC; TANG CAPITAL PARTNERS LP; TANG KEVIN CPurchase (P)Common Stock636,675USD 14.35USD 9,137,026SEC filing ↗

Form 4 evidence

14 transaction lines in the latest 365-day window; 122 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-06White Marvin LOption exercise / conversion (M)Common Stock1,666USD —USD —SEC filing ↗
2026-08-06White Marvin LTax withholding (F)Common Stock406USD 4.07USD 1,652SEC filing ↗
2026-08-06Taylor DaphneOption exercise / conversion (M)Common Stock638USD —USD —SEC filing ↗
Show recent Form 4 evidence (14 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-06White Marvin LOption exercise / conversion (M)Common Stock1,666USD —USD —SEC filing ↗
2026-08-06White Marvin LTax withholding (F)Common Stock406USD 4.07USD 1,652SEC filing ↗
2026-08-06Taylor DaphneOption exercise / conversion (M)Common Stock638USD —USD —SEC filing ↗
2026-08-06Niederhuber JohnOption exercise / conversion (M)Common Stock400USD —USD —SEC filing ↗
2026-08-06Lamothe Jeffrey G.Option exercise / conversion (M)Common Stock961USD —USD —SEC filing ↗
2026-08-06Kwon SoYoungOption exercise / conversion (M)Common Stock638USD —USD —SEC filing ↗
2026-08-06Kunz Barbara LopezOption exercise / conversion (M)Common Stock400USD —USD —SEC filing ↗
2026-08-06Huebner DirkOption exercise / conversion (M)Common Stock638USD —USD —SEC filing ↗
2026-08-06Huebner DirkTax withholding (F)Common Stock156USD 4.07USD 635SEC filing ↗
2026-08-06Harsanyi ZsoltOption exercise / conversion (M)Common Stock400USD —USD —SEC filing ↗
2026-08-06Grant Grady IIIOption exercise / conversion (M)Common Stock400USD —USD —SEC filing ↗
2026-08-06Abdun-Nabi DanielOption exercise / conversion (M)Common Stock400USD —USD —SEC filing ↗
2026-07-17White Marvin LOption exercise / conversion (M)Common Stock1USD —USD —SEC filing ↗
2025-11-10Grant Grady IIIPurchase (P)Common Stock13,513USD 1.49USD 20,134SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerAPVO
CIK0001671584
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history122 transaction lines from 2020-11-04 to 2026-08-06
17 P purchase lines · 17 S sale lines · 88 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.